Details for Patent: 12,252,478

Which drugs does patent 12,252,478 protect, and when does it expire?

Patent 12,252,478 protects SCEMBLIX and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 12,252,478

Title:	Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Abstract:	The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
Inventor(s):	Stephanie Kay Dodd, Arnaud Grandeury, Emmanuel SUFFERT, Evgenia ROUSAKI
Assignee:	Novartis AG , Novartis Pharma AG
Application Number:	US17/858,701
Patent Claim Types: see list of patent claims	Composition; Process; Dosage form;

Drugs Protected by US Patent 12,252,478

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No			Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-002	Oct 29, 2021		RX	Yes	No			Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes			Y

International Family Members for US Patent 12,252,478

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020276701
Brazil	112021022712
Canada	3139812